Acandis's Aperio Hybrid Stroke Thrombectomy Device Approved in Europe

 

June 5, 2019—Acandis GmbH announced that it has received European CE Mark approval for its Aperio hybrid thrombectomy device, which is intended for restoration of arterial flow in patients diagnosed with ischemic stroke caused by large intracranial vascular occlusion. Acandis, which is based in Pforzheim, Germany, is focused on neurointerventional devices for the prevention and treatment of strokes.

The Aperio device is the new generation of the Acandis stent retriever. Aperio's visibility, vessel wall apposition, and expansion into the clot provide for efficient clot retention and fast flow restoration.

According to the company, the device combines a hybrid cell design with a new visibility concept for more safety and control. Additionally, radiopaque DFT wires allow full-length visibility of the device for precise alignment and permanent control during the procedure.

The Aperio hybrid thrombectomy device is suitable for vessel diameters from 1.5 to 5.5 mm and can be delivered through common 0.021-inch microcatheters, stated Acandis.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.